Circulating immune complexes and granulocytes chemotaxis in Kawasaki disease. 1984

K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki

Serum immunoglobulin levels, complement titers, circulating immune complex levels, and chemotaxis of granulocytes were evaluated in 32 patients with Kawasaki disease with or without coronary aneurysm. The group of patients with coronary aneurysm showed relatively higher levels of IgG. Regardless of the presence of coronary aneurysm, the level of IgE in the acute phase was higher than that in the convalescent phase. The level of immune complexes was higher in the group of patients with coronary aneurysm (p less than 0.05). There was a low negative correlation between immune complexes and CH50. The chemotaxis of the patients with coronary aneurysm was significantly impaired (p less than 0.01).

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D009080 Mucocutaneous Lymph Node Syndrome An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities. Kawasaki Disease,Lymph Node Syndrome, Mucocutaneous,Kawasaki Syndrome
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003181 Complement C4 A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B. C4 Complement,C4 Complement Component,Complement 4,Complement C4, Precursor,Complement Component 4,Pro-C4,Pro-complement 4,C4, Complement,Complement Component, C4,Complement, C4,Component 4, Complement,Component, C4 Complement,Pro C4,Pro complement 4
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary

Related Publications

K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
May 1988, European journal of pediatrics,
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
January 1987, Progress in clinical and biological research,
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
January 1985, Pediatric infectious disease,
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
March 1979, La Nouvelle presse medicale,
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
March 1979, Archives of disease in childhood,
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
October 1989, Zhonghua yi xue za zhi,
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
January 2022, International immunopharmacology,
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
January 1984, Arerugi = [Allergy],
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
August 1982, Atherosclerosis,
K Miyata, and K Kawakami, and T Onimaru, and Y Baba, and S Ono, and M Hokonohara, and M Yoshinaga, and T Terawaki
February 1978, The American journal of medicine,
Copied contents to your clipboard!